Abstract

Patients with Type II diabetes mellitus or the metabolic syndrome have unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol. Treatment of dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity. Statins and fibrates are useful for treating elevated LDL in patients with and without diabetes or the metabolic syndrome. There are few researches on Apolipoprotein A and Apolipoprotein B, Lipoprotein (a) in India, in comparison to foreign countries. So this study is aimed to evaluate Apo lipoproteins (Apo A1 & Apo B) and Lipoprotein (a) levels along with Lipid profile in Type II Diabetes Mellitus and in patients with Metabolic Syndrome which can be correlated with the risk of cardiovascular disease.
 Conclusion: Apo lipoprotein A1, Apolipoprotein B and Lipoprotein (a) can be important marker for the risk developing of heart disease. Statistical relationships between LDL and HDL and their respective Apo lipoproteins, Apo B and Apo A-1, in diabetic and metabolic syndrome can be established.
 Keywords: Lipid profile, Type II Diabetes Mellitus, Apo lipoproteins (Apo A & Apo B), Lipoprotein (a) and Metabolic Syndrome.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.